Biblio

33557 resultats trouvés
A
Creutzberg CL, de Boer SM, Putter H, Powell M, Mileshkin LR, Katsaros D, Bessette P, Haie-Meder C, Ledermann JA, Ottevanger P.B et al..  2015.  Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial.. JOURNAL OF CLINICAL ONCOLOGY. 33
Pivot X.  2014.  Adjuvant chemotherapy for local relapse breast cancer. LANCET ONCOLOGY. 15:125-126.
Bosset J-F, Collette L.  2014.  Adjuvant chemotherapy for rectal cancer Reply. LANCET ONCOLOGY. 15:E197-E198.
Harshman LChristine, Werner L, Wong Y-N, Yu EY, Alva AShivaram, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN et al..  2015.  Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC). JOURNAL OF CLINICAL ONCOLOGY. 33
Berthelot A., De Nonneville A., Classe J.-M, Cohen M., Reyal F., Mazouni C., Chauvet M.P, Martinez A., Chopin N., Darai E. et al..  2019.  Adjuvant chemotherapy in elderly breast cancer patients: Pattern of use and impact on overall survival. ANNALS OF ONCOLOGY. 30
de Nonneville A, Jauffret C, Goncalves A, Classe J-M, Cohen M, Reyal F, Mazouni C, Chauvet M-P, Chopin N, Colombo P-E et al..  2019.  Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit. BREAST CANCER RESEARCH AND TREATMENT. 175:379-387.
Boustani J., Caubet M., Bosset J.-F.  2016.  Adjuvant Chemotherapy in Rectal Cancer after Chemoradiotherapy. CLINICAL ONCOLOGY. 28:140-145.
Eveno C, Adenis A, Bouche O, Le Malicot K, Hautefeuille V, Faroux R, Bidault AThirot, Egreteau J, Meunier B, Mabro M et al..  2019.  Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19).. JOURNAL OF CLINICAL ONCOLOGY. 37
Andre T, De Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JLuc et al..  2015.  Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. JOURNAL OF CLINICAL ONCOLOGY. 33:4176+.
Taieb J., Balogoun R., Le Malicot K., Tabernero J., Mini E., Folprecht G., Van Laethem J.-L, Emile J.-F, Mulot C., Fratte S. et al..  2017.  Adjuvant FOLFOX plus /- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients. ANNALS OF ONCOLOGY. 28:824-830.
Taieb J., Le Malicot K., Balogoum R., Tabernero J., Mini E., Folprecht G., van Laethem J-L., Emile J-F., Mulot C., Fratte S. et al..  2016.  Adjuvant FOLFOX plus cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial. ANNALS OF ONCOLOGY. 27
Edeline J., Hirano S., Bertaut A., Konishi M., Benabdelghani M., Uesaka K., Watelet J., Ohtsuka M., Hammel P., Kaneoka Y. et al..  2020.  Adjuvant gemcitabine-based chemotherapy for biliary tract cancer: Pooled analysis of the BCAT and PRODIGE-12 studies. ANNALS OF ONCOLOGY. 31:S262.
Edeline J., Bonnetain F., Phelip J-M., Watelet J., Hammel P., Joly J-P., Benabdelghani M., Fartoux L., Bouhier-Leporrier K., Jouve J-L. et al..  2017.  Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. ANNALS OF ONCOLOGY. 28
Edeline J., Bonnetain F., Phelip J-M., Watelet J., Hammel P., Joly J-P., Benabdelghani M., Fartoux L., Bouhier-Leporrier K., Jouve J-L. et al..  2017.  Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. ANNALS OF ONCOLOGY. 28
Pourcelot C, Orillard E, Nallet G, Dirand C, Billion-Rey F, Barbier G, Chouk S, Limat S, Montcuquet P, Henriques J et al..  2018.  Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence. BREAST CANCER RESEARCH AND TREATMENT. 169:153-162.
Vardanega J, Henriques J, Pourcelot C, Dirand C, Nallet G, Bredart A, Anota A, Chaigneau L, Curtit E, Limat S et al..  2019.  Adjuvant hormonal therapy for early breast cancer: Assessment of patients' satisfaction. BULLETIN DU CANCER. 106:1104-1114.
Choueiri T.K, Tomczak P., Park S.H, Venugopal B., Ferguson T., Chang Y.-H, Hajek J., Symeonides S.N, Lee J.L, Sarwar N. et al..  2021.  Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. NEW ENGLAND JOURNAL OF MEDICINE. 385:683-694.
Jung K.H, Ataseven B., Verrill M., Pivot X., De Laurentiis M., Al-Sakaff N., Lauer S., Shing M., Gligorov J., Azim H.A.  2016.  Adjuvant subcutaneous trastuzumab for HER2-positive early breast cancer: Phase III SafeHer study subgroup analyses of body weights, active medical conditions, safety and tolerability. ANNALS OF ONCOLOGY. 27
Bouvier AMarie, Crehange G, Azelie C, Cheynel N, Jouve JLouis, Bedenne L, Faivre J, Lepage C, Maingon P.  2014.  Adjuvant treatments for gastric cancer: From practice guidelines to clinical practice. DIGESTIVE AND LIVER DISEASE. 46:72-75.
Bordy R, Moretto J, Devaux S, Wendling D, Moretto-Riedweg K, Demougeot C, Totoson P.  2021.  Adjuvant-induced arthritis is a relevant model to mimic coronary and myocardial impairments in rheumatoid arthritis. JOINT BONE SPINE. 88:105069.
Delva F, Touraine C, Joly P, Edjolo A, Amieva H, Berr C, Rouaud O, Helmer C, Peres K, Dartigues J-F.  2016.  ADL disability and death in dementia in a French population-based cohort: New insights with an illness-death model. ALZHEIMERS & DEMENTIA. 12:909-916.
Petithomme M.  2020.  Administration and Dependence in a de facto State: the Ambivalence of the statization in Northern Cyprus. CAHIERS BALKANIQUES. 46:13597.
Lesieur O, Quenot JPierre, Cohen-Solal Z, David R, Blanquat LDe Saint, Elbaz M, Le Roux BGaillard, Goulenok C, Lavoue S, Lemiale V et al..  2021.  Admission criteria and management of critical care patients in a pandemic context: position of the Ethics Commission of the French Intensive Care Society, update of April 2021. ANNALS OF INTENSIVE CARE. 11:66.
Schiele F, Bueno H, Hochadel M, Tubaro M, Meneveau N, Wojakowski W, Gierlotka M, Bassand J-P, Fox K, Gitt A.  2014.  ADMISSION HYPERGLYCEMIA IMPROVES THE GRACE RISK SCORE FOR PREDICTION OF IN-HOSPITAL MORTALITY: INSIGHTS FROM THE EURO HEART SURVEY ACS III. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 63:A47.
Schiele F., Bueno H., Hochadel M., Tubaro M., Meneveau N., Wojakowski W., Gierlotka M., Bassand J.P, Fox K.AA, Gitt A.K.  2014.  Admission hyperglycemia improves the GRACE risk score for prediction of in-hospital mortality. Insights from the Euro Heart Survey ACS III. EUROPEAN HEART JOURNAL. 35:153.

Pages